Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

113 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-06

Study Completion Date

2020-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting therapeutic outcome and individualized dosage remains to be a challenge. The study's objective is to identify the genetic and clinical factors that can influence clinical outcome in liver transplant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy

NCT03764670

Kidney Transplantation

COMPLETED

Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient

NCT03256864

Liver Transplantation

COMPLETED PHASE4

Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients

NCT06183892

Liver Transplant

RECRUITING NA

Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation

NCT06319391

Complete and Accurate Statistical Data of 60 Patients CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients +2 more

ACTIVE_NOT_RECRUITING

Dosage of Tacrolimus Metabolites in Blood and Bile for Prediction of Its Side Effects in Liver Transplant Recipients

NCT05277792

Blood Concentration of Tacrolimus Metabolites

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A great number of studies had found significant correlation between tacrolimus pharmacokinetics and gene polymorphism. However, previous studies on the correlation between genetic factors and clinical outcome were controversial. Furthermore, most studies focused on single genetic polymorphism and clinical outcome, and very limited studies took multiple genetic factors and clinical factors into account.

This is a retrospective study. Eligible patients were those who had signed informed consent for genetic study in previous research projects ( IRB approval number：201512005RINC and 201612023RIND ). The present study will collect laboratory data, concurrent medications, and therapeutic drug monitoring (TDM) data. Patient survival, graft survival, acute rejection and tacrolimus-associated adverse events will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who underwent living-donor liver transplantation during January 2008 to December 2017
* at the age of 20-65
* with tacrolimus-based immunosuppression after liver transplant for at least 6 months.